Literature DB >> 33783722

A novel deletion variant in CLN3 with highly variable expressivity is responsible for juvenile neuronal ceroid lipofuscinoses.

Naser Gilani1,2, Ehsan Razmara3, Mehmet Ozaslan4, Ihsan Kareem Abdulzahra5, Saeid Arzhang6, Ali Reza Tavasoli7, Masoud Garshasbi8.   

Abstract

Mutations in CLN3 (OMIM: 607042) are associated with juvenile neuronal ceroid lipofuscinoses (JNCL)-a rare neurodegenerative disease with early retinal degeneration and progressive neurologic deterioration. The study aimed to determine the underlying genetic factors justifying the NCL phenotype in a large Iraqi consanguineous family. Four affected individuals with an initial diagnosis of NCL were recruited. By doing neuroimaging and also pertinent clinical examinations, e.g. fundus examination, due to heterogeneity of neurodevelopmental disorders, the proband was subjected to the paired-end whole-exome sequencing to identify underlying genetic factors. The candidate variant was also confirmed by Sanger sequencing. Various in silico predictions were used to show the pathogenicity of the variant. This study revealed a novel homozygous frameshift variant-NM_000086.2: c.1127del; p.(Leu376Argfs*15)-in the exon 14 of the CLN3 gene as the most likely disease-causing variant. Three out of 4 patients showed bilateral vision loss (< 7 years) and retinal degeneration with macular changes in both eyes. Electroencephalography demonstrated the loss of normal posterior alpha rhythm and also low amplitude multifocal slow waves. Brain magnetic resonance imaging of the patients with a high degree of deterioration showed mild cerebral and cerebellar cortical atrophy, mild ventriculomegaly, thinning of the corpus callosum and vermis, and non-specific periventricular white matter signal changes in the occipital area. The novel biallelic deletion variant of CLN3 was identified that most probably led to JNCL with variable expressivity of the phenotype. This study also expanded our understanding of the clinical and genetic spectrum of JNCL.

Entities:  

Keywords:  CLN3; Juvenile neuronal ceroid lipofuscinoses; Variable expressivity; Whole-exome sequencing

Year:  2021        PMID: 33783722     DOI: 10.1007/s13760-021-01655-9

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  46 in total

Review 1.  Neural and extraneural expression of the neuronal ceroid lipofuscinoses genes CLN1, CLN2, and CLN3: functional implications for CLN3.

Authors:  S Chattopadhyay; D A Pearce
Journal:  Mol Genet Metab       Date:  2000 Sep-Oct       Impact factor: 4.797

2.  Batten disease: features to facilitate early diagnosis.

Authors:  J Collins; G E Holder; H Herbert; G G W Adams
Journal:  Br J Ophthalmol       Date:  2006-06-05       Impact factor: 4.638

Review 3.  You say lipofuscin, we say ceroid: defining autofluorescent storage material.

Authors:  Sabrina S Seehafer; David A Pearce
Journal:  Neurobiol Aging       Date:  2006-02-07       Impact factor: 4.673

4.  Neuronal ceroid lipofuscinosis: a common pathway?

Authors:  Dixie-Ann Persaud-Sawin; Talal Mousallem; Christine Wang; Adam Zucker; Eiki Kominami; Rose-Mary N Boustany
Journal:  Pediatr Res       Date:  2007-02       Impact factor: 3.756

Review 5.  Juvenile neuronal ceroid lipofuscinosis (JNCL) and the eye.

Authors:  Sara Bozorg; Denia Ramirez-Montealegre; Mina Chung; David A Pearce
Journal:  Surv Ophthalmol       Date:  2009 Jul-Aug       Impact factor: 6.048

Review 6.  Selectivity and types of cell death in the neuronal ceroid lipofuscinoses.

Authors:  Hannah M Mitchison; Ming J Lim; Jonathan D Cooper
Journal:  Brain Pathol       Date:  2004-01       Impact factor: 6.508

Review 7.  The dystrophic retina in multisystem disorders: the electroretinogram in neuronal ceroid lipofuscinoses.

Authors:  R G Weleber
Journal:  Eye (Lond)       Date:  1998       Impact factor: 3.775

8.  CLN5, a novel gene encoding a putative transmembrane protein mutated in Finnish variant late infantile neuronal ceroid lipofuscinosis.

Authors:  M Savukoski; T Klockars; V Holmberg; P Santavuori; E S Lander; L Peltonen
Journal:  Nat Genet       Date:  1998-07       Impact factor: 38.330

9.  Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy.

Authors:  Genevieve A Wright; Michalis Georgiou; Anthony G Robson; Naser Ali; Ambreen Kalhoro; Sm Kleine Holthaus; Nikolas Pontikos; Ngozi Oluonye; Emanuel R de Carvalho; Magella M Neveu; Richard G Weleber; Michel Michaelides
Journal:  Ophthalmol Retina       Date:  2019-11-13

Review 10.  The CLN3 gene and protein: What we know.

Authors:  Myriam Mirza; Anna Vainshtein; Alberto DiRonza; Uma Chandrachud; Luke J Haslett; Michela Palmieri; Stephan Storch; Janos Groh; Niv Dobzinski; Gennaro Napolitano; Carolin Schmidtke; Danielle M Kerkovich
Journal:  Mol Genet Genomic Med       Date:  2019-09-30       Impact factor: 2.183

View more
  2 in total

1.  Novel manifestations of Warburg micro syndrome type 1 caused by a new splicing variant of RAB3GAP1: a case report.

Authors:  Raziyeh Khalesi; Ehsan Razmara; Golareh Asgaritarghi; Ali Reza Tavasoli; Yasser Riazalhosseini; Daniel Auld; Masoud Garshasbi
Journal:  BMC Neurol       Date:  2021-04-28       Impact factor: 2.903

2.  A Novel, Apparently Silent Variant in MFSD8 Causes Neuronal Ceroid Lipofuscinosis with Marked Intrafamilial Variability.

Authors:  Milda Reith; Lena Zeltner; Karin Schäferhoff; Dennis Witt; Theresia Zuleger; Tobias B Haack; Antje Bornemann; Michael Alber; Susanne Ruf; Ludger Schoels; Katarina Stingl; Nicole Weisschuh
Journal:  Int J Mol Sci       Date:  2022-02-18       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.